Delineating the role of nuclear receptors in colorectal cancer, a focused review

1.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

2.

Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34:573–80. https://doi.org/10.1097/COC.0b013e3181fe41ed.CrossRefPubMed

3.

Thanikachalam K, Khan G. Colorectal cancer and nutrition. Nutrients. 2019. https://doi.org/10.3390/nu11010164.CrossRefPubMedPubMedCentral

4.

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64. https://doi.org/10.3322/caac.21601.CrossRefPubMed

5.

Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund/American institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr. 2020;150:663–71.PubMedCrossRef

6.

Harsha C, Banik K, Bordoloi D, Kunnumakkara AB. Antiulcer properties of fruits and vegetables: a mechanism based perspective. Food Chem Toxicol. 2017;108:104–19. https://doi.org/10.1016/j.fct.2017.07.023.CrossRefPubMed

7.

Grassadonia A, Di Marino P, Ficorella C, Cortellini A, Cannita K, Parisi A, Gamucci T, Zoratto F, Vici P, Barba M, et al. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. J Cancer. 2019;10:5926–34. https://doi.org/10.7150/jca.34550.CrossRefPubMedPubMedCentral

8.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93. https://doi.org/10.3322/caac.21395.CrossRefPubMed

9.

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54. https://doi.org/10.3322/caac.21772.CrossRefPubMed

10.

Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–49. https://doi.org/10.1136/gutjnl-2014-309086.CrossRefPubMed

11.

Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev. 2012;21:411–6. https://doi.org/10.1158/1055-9965.EPI-11-1020.CrossRefPubMed

12.

Sanchez-Guillen L, Arroyo A. Immunonutrition in patients with colon cancer. Immunotherapy. 2020;12:5–8. https://doi.org/10.2217/imt-2019-0179.CrossRefPubMed

13.

Kumar A, Singam A, Swaminathan G, Killi N, Tangudu NK, Jose J, Gundloori Vn R, Dinesh Kumar L. Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models. Nanoscale. 2022;14:492–505. https://doi.org/10.1039/d1nr04411g.CrossRefPubMed

14.

Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S, Cecka F, Krupova M, Manethova M, Cervena K, et al. Distant metastasis in colorectal cancer patients-do we have new predicting clinicopathological and molecular biomarkers? A comprehensive review. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155255.CrossRefPubMedPubMedCentral

15.

Muralimanoharan SB, Kunnumakkara AB, Shylesh B, Kulkarni KH, Haiyan X, Ming H, Aggarwal BB, Rita G, Kumar AP. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2009;69:494–504. https://doi.org/10.1002/pros.20899.CrossRefPubMedPubMedCentral

16.

Sajeev A, Hegde M, Daimary UD, Kumar A, Girisa S, Sethi G, Kunnumakkara AB. Modulation of diverse oncogenic signaling pathways by oroxylin A: an important strategy for both cancer prevention and treatment. Phytomedicine. 2022;105:154369. https://doi.org/10.1016/j.phymed.2022.154369.CrossRefPubMed

17.

Sajeev A, Hegde M, Girisa S, Devanarayanan TN, Alqahtani MS, Abbas M, Sil SK, Sethi G, Chen JT, Kunnumakkara AB. Oroxylin A: a promising flavonoid for prevention and treatment of chronic diseases. Biomolecules. 2022. https://doi.org/10.3390/biom12091185.CrossRefPubMedPubMedCentral

18.

Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Tong Z, Gelovani JG, Guha S, et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. 2012;131:E292-303. https://doi.org/10.1002/ijc.26442.CrossRefPubMed

19.

Padmavathi G, Rathnakaram SR, Monisha J, Bordoloi D, Roy NK, Kunnumakkara AB. Potential of butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine. 2015;22:1163–71.PubMedCrossRef

20.

Henamayee S, Banik K, Sailo BL, Shabnam B, Harsha C, Srilakshmi S, Vgm N, Baek SH, Ahn KS, Kunnumakkara AB. Therapeutic emergence of rhein as a potential anticancer drug: a review of its molecular targets and anticancer properties. Molecules. 2020;25:2278.PubMedPubMedCentralCrossRef

21.

Nair A, Amalraj A, Jacob J, Kunnumakkara AB, Gopi S. Non-curcuminoids from turmeric and their potential in cancer therapy and anticancer drug delivery formulations. Biomolecules. 2019;9:13.PubMedPubMedCentralCrossRef

22.

Singh YP, Girisa S, Banik K, Ghosh S, Swathi P, Deka M, Padmavathi G, Kotoky J, Sethi G, Fan L. Potential application of zerumbone in the prevention and therapy of chronic human diseases. J Funct Foods. 2019;53:248–58.CrossRef

23.

Devi Daimary U, Girisa S, Parama D, Verma E, Kumar A, Kunnumakkara AB. Embelin: A novel XIAP inhibitor for the prevention and treatment of chronic diseases. J Biochem Mol Toxicol. 2022;36:e22950.PubMedCrossRef

24.

Verma E, Kumar A, Devi Daimary U, Parama D, Girisa S, Sethi G, Kunnumakkara AB. Potential of baicalein in the prevention and treatment of cancer: a scientometric analyses based review. J Funct Foods. 2021;86:104660. https://doi.org/10.1016/j.jff.2021.104660.CrossRef

25.

Girisa S, Shabnam B, Monisha J, Fan L, Halim CE, Arfuso F, Ahn KS, Sethi G, Kunnumakkara AB. Potential of zerumbone as an anti-cancer agent. Molecules. 2019. https://doi.org/10.3390/molecules24040734.CrossRefPubMedPubMedCentral

26.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–91.PubMedCrossRef

27.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–75.PubMedCrossRef

28.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.PubMedCrossRef

29.

Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245. https://doi.org/10.3389/fphar.2018.00245.CrossRefPubMedPubMedCentral

30.

Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, et al. NGAL is downregulated in oral squamous cell carcinoma and leads to increased survival, proliferation, migration and chemoresistance. Cancers (Basel). 2018. https://doi.org/10.3390/cancers10070228.CrossRefPubMedPubMedCentral

31.

Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, Shakibaei M, Gupta SC, Aggarwal BB. Cancer drug development: The missing links. Exp Biol Med. 2019;244:663–89.CrossRef

32.

Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22. https://doi.org/10.1038/s41392-020-0116-z.CrossRefPubMedPubMedCentral

33.

Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013;6:801–10. https://doi.org/10.1158/1940-6207.CAPR-13-0058-T.CrossRefPubMed

34.

Buhrmann C, Kunnumakkara AB, Kumar A, Samec M, Kubatka P, Aggarwal BB, Shakibaei M. Multitargeting effects of calebin A on malignancy of CRC cells in multicellular tumor microenvironment. Front Oncol. 2021;11: 650603. https://doi.org/10.3389/fonc.2021.650603.CrossRefPubMedPubMedCentral

35.

Gangwar SK, Kumar A, Jose S, Alqahtani MS, Abbas M, Sethi G, Kunnumakkara AB. Nuclear receptors in oral cancer-Emerging players in tumorigenesis. Cancer Lett. 2022;536: 215666. https://doi.org/10.1016/j.canlet.2022.215666.CrossRefPubMed

36.

Frigo DE, Bondesson M, Williams C. Nuclear receptors: from molecular mechanisms to therapeutics. Essays Biochem. 2021;65:847–56. https://doi.org/10.1042/EBC20210020.CrossRefPubMedPubMedCentral

37.

Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.PubMedCrossRef

38.

Bluemn E, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24:251.PubMedPubMedCentralCrossRef

39.

Long MD, Campbell MJ. Pan-cancer analyses of the nuclear receptor superfamily. Nucl Receptor Res. 2015. https://doi.org/10.11131/2015/101182.CrossRefPubMedPubMedCentral

40.

Thomas C, Gustafsson J-Å. Estrogen receptor mutations and functional consequences for breast cancer. Trends Endocrinol Metab. 2015;26:467–76.PubMedCrossRef

41.

Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta. 2011;1812:893–908.PubMedCrossRef

42.

Gangwar SK, Kumar A, Yap KC, Jose S, Parama D, Sethi G, Kumar AP, Kunnumakkara AB. Targeting nuclear receptors in lung cancer-novel therapeutic prospects. Pharmaceuticals. 2022. https://doi.org/10.3390/ph15050624.CrossRefPubMedPubMedCentral

43.

Girisa S, Henamayee S, Parama D, Rana V, Dutta U, Kunnumakkara AB. Targeting farnesoid X receptor (FXR) for developing novel therapeutics against cancer. Mol Biomed. 2021;2:21. https://doi.org/10.1186/s43556-021-00035-2.CrossRefPubMedPubMedCentral

44.

Girisa S, Rana V, Parama D, Dutta U, Kunnumakkara AB. Differential roles of farnesoid X receptor (FXR) in modulating apoptosis in cancer cells. Adv Protein Chem Struct Biol. 2021;126:63–90.PubMedCrossRef

45.

Yen PM. Classical nuclear hormone receptor activity as a mediator of complex biological responses: a look at health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29:517–28. https://doi.org/10.1016/j.beem.2015.07.005.CrossRefPubMed

46.

Lin JH, Giovannucci E. Sex hormones and colorectal cancer: what have we learned so far? J Natl Cancer Inst. 2010;102:1746–7.PubMedPubMedCentralCrossRef

47.

Alberg AJ, Gordon GB, Hoffman SC, Comstock GW, Helzlsouer KJ. Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. Cancer Epidemiol Biomark Prev. 2000;9:517–21.

48.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004.PubMedCrossRef

49.

Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W. Associations between ERα, ERβ, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomark Prev. 2005;14:2936–42.CrossRef

50.

Anagnostopoulou V, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, Gravanis A, Charalampopoulos I, Stournaras C. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology. 2013;154:2446–56. https://doi.org/10.1210/en.2012-2249.CrossRefPubMed

51.

Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci. 2014;111:16514–9.ADSPubMedPubMedCentralCrossRef

52.

Flanagan JJ, Neklesa TK. Targeting Nuclear Receptors with PROTAC degraders. Mol Cell Endocrinol. 2019;493: 110452. https://doi.org/10.1016/j.mce.2019.110452.CrossRefPubMed

53.

Cathcart P, Lucchesi W, Ottaviani S, De Giorgio A, Krell J, Stebbing J, Castellano L. Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29:529–43. https://doi.org/10.1016/j.beem.2015.07.003.CrossRefPubMed

54.

Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov. 2014;13:197–216. https://doi.org/10.1038/nrd4100.CrossRefPubMedPubMedCentral

55.

Yang Z, Gimple RC, Zhou N, Zhao L, Gustafsson JA, Zhou S. Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges. Trends Cancer. 2021;7:541–56. https://doi.org/10.1016/j.trecan.2020.11.007.CrossRefPubMed

56.

Zhao L, Hu H, Gustafsson JA, Zhou S. Nuclear Receptors in Cancer Inflammation and Immunity. Trends Immunol. 2020;41:172–85. https://doi.org/10.1016/j.it.2019.12.006.CrossRefPubMed

57.

Dhiman VK, Bolt MJ, White KP. Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. Nat Rev Genet. 2018;19:160–74. https://doi.org/10.1038/nrg.2017.102.CrossRefPubMed

58.

Zhao L, Zhou S, Gustafsson JA. Nuclear Receptors: Recent Drug Discovery for Cancer Therapies. Endocr Rev. 2019;40:1207–49. https://doi.org/10.1210/er.2018-00222.CrossRefPubMed

59.

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835.PubMedPubMedCentralCrossRef

60.

Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140:1583–91. https://doi.org/10.1182/blood.2021014760.CrossRefPubMedPubMedCentral

61.

Weikum ER, Liu X, Ortlund EA. The nuclear receptor superfamily: a structural perspective. Protein Sci. 2018;27:1876–92.PubMedPubMedCentralCrossRef

62.

Jayaprakash S, Hegde M, Girisa S, Alqahtani MS, Abbas M, Lee EHC, Yap KC-H, Sethi G, Kumar AP, Kunnumakkara AB. Demystifying the functional role of nuclear receptors in esophageal cancer. Int J Mol Sci. 2022;23:10952.PubMedPubMedCentralCrossRef

63.

Fuller PJ. The steroid receptor superfamily: mechanisms of diversity. FASEB J. 1991;5:3092–9.MathSciNetPubMedCrossRef

64.

O’Malley BW, Tsai M-J. Molecular pathways of steroid receptor action. Biol Reprod. 1992;46:163–7.PubMedCrossRef

65.

De Bosscher K, Desmet SJ, Clarisse D, Estébanez-Perpiña E, Brunsveld L. Nuclear receptor crosstalk—defining the mechanisms for therapeutic innovation. Nat Rev Endocrinol. 2020;16:363–77.PubMedCrossRef

66.

Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: Solving the puzzle with nuclear receptors. Trends Mol Med. 2011;17:564–72. https://doi.org/10.1016/j.molmed.2011.05.010.CrossRefPubMed

67.

Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev. 2005;26:898–915. https://doi.org/10.1210/er.2003-0034.CrossRefPubMed

68.

Hu J, Wang C, Huang X, Yi S, Pan S, Zhang Y, Yuan G, Cao Q, Ye X, Li H. Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep. 2021;36: 109726. https://doi.org/10.1016/j.celrep.2021.109726.CrossRefPubMed

69.

Gonzalez FJ, Jiang C, Patterson AD. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. Gastroenterology. 2016;151:845–59. https://doi.org/10.1053/j.gastro.2016.08.057.CrossRefPubMed

70.

Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, Gustafsson JA, Engstrand L, Williams C. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019;144:3086–98. https://doi.org/10.1002/ijc.32037.CrossRefPubMedPubMedCentral

71.

Catalano MG, Pfeffer U, Raineri M, Ferro P, Curto A, Capuzzi P, Corno F, Berta L, Fortunati N. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer. 2000;86:325–30. https://doi.org/10.1002/(sici)1097-0215(20000501)86:3%3c325::aid-ijc4%3e3.0.co;2-g.CrossRefPubMed

72.

Albasri AM, Elkablawy MA. Clinicopathological and prognostic significance of androgen receptor overexpression in colorectal cancer. Experience from Al-Madinah Al-Munawarah. Saudi Arabia Saudi Med J. 2019;40:893–900. https://doi.org/10.15537/smj.2019.9.24204.CrossRefPubMed

73.

Castagnetta L, Traina A, Campisi I, Calabro M, Maratta A, Saetta A, Agostara B, Mezzatesta N. Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann N Y Acad Sci. 2002;963:322–5. https://doi.org/10.1111/j.1749-6632.2002.tb04124.x.ADSCrossRefPubMed

74.

Stebbings WS, Farthing MJ, Vinson GP, Northover JM, Wood RF. Androgen receptors in rectal and colonic cancer. Dis Colon Rectum. 1986;29:95–8. https://doi.org/10.1007/BF02555385.CrossRefPubMed

75.

Li XB, Jiao S, Sun H, Xue J, Zhao WT, Fan L, Wu GH, Fang J. The orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells. Cancer Lett. 2011;309:137–44. https://doi.org/10.1016/j.canlet.2011.05.025.CrossRefPubMed

76.

Zhou ZW, Wan DS, Wang GQ, Pan ZZ, Lu HP, Gao JH, Ding PR. Expression of estrogen receptor and progesterone receptor in colorectal cancer: a quantitative study. Ai Zheng. 2004;23:851–4.PubMed

77.

Nüssler NC, Reinbacher K, Shanny N, Schirmeier A, Glanemann M, Neuhaus P, Nussler AK, Kirschner M. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med. 2008;5:209–17.PubMedCrossRef

78.

Jiang HP, Teng RY, Wang Q, Zhang X, Wang HH, Cao J, Teng LS. Estrogen receptor alpha variant ERalpha46 mediates growth inhibition and apoptosis of human HT-29 colon adenocarcinoma cells in the presence of 17beta-oestradiol. Chin Med J (Engl). 2008;121:1025–31.PubMedCrossRef

79.

Jiang L, Fei H, Yang A, Zhu J, Sun J, Liu X, Xu W, Yang J, Zhang S. Estrogen inhibits the growth of colon cancer in mice through reversing extracellular vesicle-mediated immunosuppressive tumor microenvironment. Cancer Lett. 2021;520:332–43.PubMedCrossRef

80.

Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumors. Carcinogenesis. 2004;25:1917–23.PubMedCrossRef

81.

Armstrong CM, Billimek AR, Allred KF, Sturino JM, Weeks BR, Allred CD. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. Endocr Relat Cancer. 2013;20:515–25.PubMedCrossRef

82.

Topi G, Ghatak S, Satapathy SR, Ehrnström R, Lydrup M-L, Sjölander A. Combined estrogen alpha and beta receptor expression has a prognostic significance for colorectal cancer patients. Front Med. 2022;9:739620.CrossRef

83.

Castiglione F, Taddei A, Degl’Innocenti DR, Buccoliero AM, Bechi P, Garbini F, Chiara FG, Moncini D, Cavallina G, Marascio L. Expression of estrogen receptor β in colon cancer progression. Diagn Mol Pathol. 2008;17:231–6.PubMedCrossRef

84.

Edvardsson K, Nguyen-Vu T, Kalasekar SM, Pontén F, Gustafsson J-Å, Williams C. Estrogen receptor β expression induces changes in the microRNA pool in human colon cancer cells. Carcinogenesis. 2013;34:1431–41.PubMedCrossRef

85.

Peng J, Ou Q, Wu X, Zhang R, Zhao Q, Jiang W, Lu Z, Wan D, Pan Z, Fang Y. Expression of voltage-gated sodium channel Nav1.5 in non-metastatic colon cancer and its associations with estrogen receptor (ER)-beta expression and clinical outcomes. Chin J Cancer. 2017. https://doi.org/10.1186/s40880-017-0253-0.CrossRefPubMedPubMedCentral

86.

Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson J-A. Tumor repressive functions of estrogen receptor β in SW480 colon cancer cells. Can Res. 2009;69:6100–6.CrossRef

87.

López-Calderero I, Carnero A, Astudillo A, Palacios J, Chaves M, Benavent M, Limón ML, Garcia-Carbonero R. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients. Hum Pathol. 2014;45:2437–46.PubMedCrossRef

88.

Motylewska E, Stasikowska O, Mełeń-Mucha G. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett. 2009;276:68–73.PubMedCrossRef

89.

Ya G, Wang H, Ma Y, Hu A, Ma Y, Hu J, Yu Y. Serum miR-129 functions as a biomarker for colorectal cancer by targeting estrogen receptor (ER) β. Die Pharmazie Intl J Pharm Sci. 2017;72:107–12.

90.

Mostafaie N, Kállay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, Huber KR, Krugluger W. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009;48:642–7.PubMedCrossRef

91.

Topi G, Ehrnström R, Jirström K, Palmquist I, Lydrup M-L, Sjölander A. Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer. Eur J Cancer. 2017;83:279–89.PubMedCrossRef

92.

Konstantinopoulos P, Kominea A, Vandoros G, Sykiotis G, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou A. Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251–8.PubMedCrossRef

93.

Hases L, Indukuri R, Birgersson M, Nguyen-Vu T, Lozano R, Saxena A, Hartman J, Frasor J, Gustafsson J-Å, Katajisto P. Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. Cancer Lett. 2020;492:54–62.PubMedCrossRef

94.

Janakiram NB, Mohammed A, Zhang Y, Brewer M, Bryant T, Lightfoot S, Steele VE, Rao CV. Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res. 2013;6:1251–61.CrossRef

95.

Nguyen-Vu T, Wang J, Mesmar F, Mukhopadhyay S, Saxena A, McCollum CW, Gustafsson JA, Bondesson M, Williams C. Estrogen receptor beta reduces colon cancer metastasis through a novel miR-205—PROX1 mechanism. Oncotarget. 2016;7:42159–71. https://doi.org/10.18632/oncotarget.9895.CrossRefPubMedPubMedCentral

96.

Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am J Pathol. 2013;183:266–76. https://doi.org/10.1016/j.ajpath.2013.03.021.CrossRefPubMed

97.

Zhou S, Xia H, Xu H, Tang Q, Nie Y, Gong QY, Bi F. ERRalpha suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. J Exp Clin Cancer Res. 2018;37:218. https://doi.org/10.1186/s13046-018-0862-8.CrossRefPubMedPubMedCentral

98.

De Vitto H, Ryu J, Calderon-Aparicio A, Monts J, Dey R, Chakraborty A, Lee MH, Bode AM, Dong Z. Estrogen-related receptor alpha directly binds to p53 and cooperatively controls colon cancer growth through the regulation of mitochondrial biogenesis and function. Cancer Metab. 2020;8:28. https://doi.org/10.1186/s40170-020-00234-5.CrossRefPubMedPubMedCentral

99.

Abou Gabal H, Ahmed N, Meckawy G, Yassin R, Hakim S. Evaluation of EZH2 and ERRalpha in colorectal carcinoma: an immunohistochemical study. Pol J Pathol. 2021;72:200–10. https://doi.org/10.5114/pjp.2021.111770.CrossRefPubMed

100.

Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, Berger A, Trauner M. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer. 2012;130:2232–9.PubMedCrossRef

101.

De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Bentzen EJ, Dufour J-F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci. 2004;49:982–9.PubMedCrossRef

102.

Yao HS, Wang J, Zhang XP, Wang LZ, Wang Y, Li XX, Jin KZ, Hu ZQ, Wang WJ. Hepatocyte nuclear factor 4alpha suppresses the aggravation of colon carcinoma. Mol Carcinog. 2016;55:458–72. https://doi.org/10.1002/mc.22294.CrossRefPubMed

103.

Wu C, Feng J, Li L, Wu Y, Xie H, Yin Y, Ye J, Li Z. Liver receptor homologue 1, a novel prognostic marker in colon cancer patients. Oncol Lett. 2018;16:2833–8. https://doi.org/10.3892/ol.2018.8988.CrossRefPubMedPubMedCentral

104.

Yan L, Qiu J, Yao J. Downregulation of microRNA-30d promotes cell proliferation and invasion by targeting LRH-1 in colorectal carcinoma. Int J Mol Med. 2017;39:1371–80. https://doi.org/10.3892/ijmm.2017.2958.CrossRefPubMedPubMedCentral

105.

Qu R, Hao S, Jin X, Shi G, Yu Q, Tong X, Guo D. MicroRNA-374b reduces the proliferation and invasion of colon cancer cells by regulation of LRH-1/Wnt signaling. Gene. 2018;642:354–61. https://doi.org/10.1016/j.gene.2017.11.019.CrossRefPubMed

106.

Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, D’Orazio A, Rainaldi S, Vacca M, Mangia A, et al. Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology. 2013. https://doi.org/10.1053/j.gastro.2013.02.005.CrossRefPubMed

107.

Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Lei P, Hamilton S, Khan S, Ramaiah SK, Safe S. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Res. 2007;67:674–83. https://doi.org/10.1158/0008-5472.CAN-06-2907.CrossRefPubMed

108.

Wu H, Lin Y, Li W, Sun Z, Gao W, Zhang H, Xie L, Jiang F, Qin B, Yan T, et al. Regulation of Nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells. FASEB J. 2011;25:192–205. https://doi.org/10.1096/fj.10-166462.CrossRefPubMedPubMedCentral

109.

Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 2006;66:4394–401. https://doi.org/10.1158/0008-5472.Can-05-4277.CrossRefPubMed

110.

Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, Wang Q, Zhao J, Lu D, Tandon M, et al. Intestinal PPARalpha protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019;157(744–759): e744. https://doi.org/10.1053/j.gastro.2019.05.057.CrossRef

111.

Martinasso G, Oraldi M, Trombetta A, Maggiora M, Bertetto O, Canuto RA, Muzio G. Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Res. 2007;2007:93416. https://doi.org/10.1155/2007/93416.CrossRefPubMedPubMedCentral

112.

Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR) δ expression in APC min/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis. 2006;27:232–9.PubMedCrossRef

113.

Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A. 2000;97:13275–80. https://doi.org/10.1073/pnas.97.24.13275.ADSCrossRefPubMedPubMedCentral

114.

Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC, Lee SI, Liang S, Gagea M, Morris JS. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression. J Natl Cancer Inst. 2014;106:052.CrossRef

115.

Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A, Papavassiliou AG. NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma “on/off” switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis. 2007;22:57–68. https://doi.org/10.1007/s00384-006-0112-y.CrossRefPubMed

116.

Qiao L, Dai Y, Gu Q, Chan KW, Ma J, Lan HY, Zou B, Rocken C, Ebert MP, Wong BC. Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett. 2008;268:260–71. https://doi.org/10.1016/j.canlet.2008.04.003.CrossRefPubMed

117.

DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998;19:49–53. https://doi.org/10.1093/carcin/19.1.49.CrossRefPubMed

118.

Tan BS, Kang O, Mai CW, Tiong KH, Khoo AS, Pichika MR, Bradshaw TD, Leong CO. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor gamma (PPARgamma). Cancer Lett. 2013;336:127–39. https://doi.org/10.1016/j.canlet.2013.04.014.CrossRefPubMed

119.

Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, Yao H, Zhou B, Tian Y. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer. 2010;102:1753–61.PubMedPubMedCentralCrossRef

120.

Raynal C, Pascussi J-M, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, Hollande F. Pregnane× Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010;9:1–13.CrossRef

121.

Jiang H, Chen K, He J, Pan F, Li J, Chen J, Chen W, Liang H. Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J Gastrointest Surg. 2009;13:1831–8.PubMedCrossRef

122.

Singh S, Sheppard MC, Langman MJ. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut. 1993;34:611–5. https://doi.org/10.1136/gut.34.5.611.CrossRefPubMedPubMedCentral

123.

Zhang YL, Wen XD, Guo X, Huang SQ, Wang TT, Zhou PT, Li W, Zhou LF, Hu YH. Progesterone suppresses the progression of colonic carcinoma by increasing the activity of the GADD45alpha/JNK/cJun signalling pathway. Oncol Rep. 2021. https://doi.org/10.3892/or.2021.8046.CrossRefPubMedPubMedCentral

124.

Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H, Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRα and PPARγ ligands to inhibit growth in human colon cancer cells—phosphorylated RXRα is a critical target for colon cancer management. Gut. 2007;56:1557–63.PubMedPubMedCentralCrossRef

125.

Modarai SR, Gupta A, Opdenaker LM, Kowash R, Masters G, Viswanathan V, Zhang T, Fields JZ, Boman BM. The anti-cancer effect of retinoic acid signaling in CRC occurs via decreased growth of ALDH+ colon cancer stem cells and increased differentiation of stem cells. Oncotarget. 2018;9:34658.PubMedPubMedCentralCrossRef

126.

Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV. Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells. Mol Cancer Ther. 2008;7:181–90. https://doi.org/10.1158/1535-7163.MCT-07-0529.CrossRefPubMed

127.

Morris J, Moseley VR, Cabang AB, Coleman K, Wei W, Garrett-Mayer E, Wargovich MJ. Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRalpha expression in human colon cancer cells. Oncotarget. 2016;7:35313–26. https://doi.org/10.18632/oncotarget.9204.CrossRefPubMedPubMedCentral

128.

Uchuya-Castillo J, Aznar N, Frau C, Martinez P, Le Nevé C, Marisa L, Penalva LO, Laurent-Puig P, Puisieux A, Scoazec J-Y. Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity. Oncotarget. 2018;9:30979.PubMedPubMedCentralCrossRef

129.

Horkko TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Makinen MJ. Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer. 2006;118:1653–9. https://doi.org/10.1002/ijc.21556.CrossRefPubMed

130.

Giardina C, Nakanishi M, Khan A, Kuratnik A, Xu W, Brenner B, Rosenberg DW. Regulation of VDR expression in Apc-mutant mice, human colon cancers and adenomas. Cancer Prev Res (Phila). 2015;8:387–99. https://doi.org/10.1158/1940-6207.CAPR-14-0371.CrossRefPubMed

131.

Zhang YG, Lu R, Wu S, Chatterjee I, Zhou D, Xia Y, Sun J. Vitamin D receptor protects against dysbiosis and tumorigenesis via the JAK/STAT pathway in intestine. Cell Mol Gastroenterol Hepatol. 2020;10:729–46. https://doi.org/10.1016/j.jcmgh.2020.05.010.CrossRefPubMedPubMedCentral

132.

Knackstedt RW, Moseley VR, Sun S, Wargovich MJ. Vitamin D receptor and retinoid X receptor alpha status and vitamin D insufficiency in models of murine colitis. Cancer Prev Res (Phila). 2013;6:585–93. https://doi.org/10.1158/1940-6207.CAPR-12-0488.CrossRefPubMed

133.

Long MD, Campbell MJ. Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer. J Steroid Biochem Mol Biol. 2017;173:130–8.PubMedCrossRef

134.

Pena C, Garcia J, Larriba M, Barderas R, Gomez I, Herrera M, García V, Silva J, Domínguez G, Rodríguez R. SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue. Oncogene. 2009;28:4375–85.PubMedCrossRef

135.

Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep. 2009;22:1021–5.PubMed

136.

Murillo G, Matusiak D, Benya RV, Mehta RG. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol. 2007;103:763–7.PubMedPubMedCentralCrossRef

137.

Larriba MJ, Martín-Villar E, García JM, Pereira F, Pena C, de Garcia Herreros A, Bonilla F, Munoz A. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis. 2009;30:1459–68.PubMedCrossRef

138.

Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57:234–40.PubMedCrossRef

139.

Prasanna R, Elbessoumy AA, Chandramoorthy HC, Dera A, Al Fayi M. FCX, an arylidene derivative, induces apoptosis in androgen receptor-selective prostate cancer cells. J Cancer Res Ther. 2021;17:401–7. https://doi.org/10.4103/jcrt.JCRT_228_17.CrossRefPubMed

140.

Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO. Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression. Cancer Immunol Res. 2020;8:1215–27. https://doi.org/10.1158/2326-6066.CIR-19-0371.CrossRefPubMedPubMedCentral

141.

Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene. 2003;22:5602–13. https://doi.org/10.1038/sj.onc.1206802.CrossRefPubMed

142.

Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, et al. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol Med. 2020;12:e9910. https://doi.org/10.15252/emmm.201809910.CrossRefPubMedPubMedCentral

143.

Picariello L, Fiorelli G, Martineti V, Tognarini I, Pampaloni B, Tonelli F, Brandi ML. Growth response of colon cancer cell lines to selective estrogen receptor modulators. Anticancer Res. 2003;23:2419–24.PubMed

144.

Yang L, Allred KF, Dykes L, Allred CD, Awika JM. Enhanced action of apigenin and naringenin combination on estrogen receptor activation in non-malignant colonocytes: implications on sorghum-derived phytoestrogens. Food Funct. 2015;6:749–55.PubMedCrossRef

145.

Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem Biophys Res Commun. 1999;261:521–7.PubMedCrossRef

146.

Janakiram NB, Steele VE, Rao CV. Estrogen receptor-β as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res. 2009;2:52–9.CrossRef

147.

Topi G, Satapathy SR, Dash P, Fred Mehrabi S, Ehrnström R, Olsson R, Lydrup ML, Sjölander A. Tumour-suppressive effect of oestrogen receptor β in colorectal cancer patients, colon cancer cells, and a zebrafish model. J Pathol. 2020;251:297–309.PubMedCrossRef

148.

Hsu H-H, Cheng S-F, Chen L-M, Liu J-Y, Chu C-H, Weng Y-J, Li Z-Y, Lin C-S, Lee S-D, Kuo W-W. Over-expressed estrogen receptor-α up-regulates hTNF-α gene expression and down-regulates β-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem. 2006;289:101–9.PubMedCrossRef

149.

Jin P, Wang D-z, Lyu C-x, Wang Y-t, He Y-q, Sheng J-q, Li X. Mismatch repair protein hMLH1, but not hMSH2, enhances estrogen-induced apoptosis of colon cancer cells. J Cancer. 2017;8:3232.PubMedPubMedCentralCrossRef

150.

Wei Y, Huang C, Wu H, Huang J. Estrogen receptor beta (ERβ) mediated-CyclinD1 degradation via autophagy plays an anti-proliferation role in colon cells. Int J Biol Sci. 2019;15:942–52.PubMedPubMedCentralCrossRef

151.

Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett. 2000;161:63–71.PubMedCrossRef

152.

Bustos V, Nolan ÁM, Nijhuis A, Harvey H, Parker A, Poulsom R, McBryan J, Thomas W, Silver A, Harvey BJ. GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget. 2017;8:84258.PubMedPubMedCentralCrossRef

153.

Raju J, Bielecki A, Caldwell D, Lok E, Taylor M, Kapal K, Curran I, Cooke GM, Bird RP, Mehta R. Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre-and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-β. J Nutr. 2009;139:474–81.PubMedCrossRef

154.

Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer. 2008;123:303–11.PubMedCrossRef

155.

He Y-q, Sheng J-q, Ling X-l, Fu L, Jin P, Yen L, Rao J. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-β in colorectal cells. Exp Mol Med. 2012;44:723–32.PubMedPubMedCentralCrossRef

156.

Fang Y-J, Pan Z-Z, Li L-R, Lu Z-H, Zhang L-Y, Wan D-S. MMP7 expression regulated by endocrine therapy in ERβ-positive colon cancer cells. J Exp Clin Cancer Res. 2009;28:1–8.CrossRef

157.

Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17β-estradiol induces ERβ up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun. 2007;359:102–7.PubMedCrossRef

158.

Qiu Y, Waters C, Lewis A, Langman M, Eggo M. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol. 2002;174:369–77.PubMedCrossRef

159.

Fiocchetti M, Camilli G, Acconcia F, Leone S, Ascenzi P, Marino M. ERβ-dependent neuroglobin up-regulation impairs 17β-estradiol-induced apoptosis in DLD-1 colon cancer cells upon oxidative stress injury. J Steroid Biochem Mol Biol. 2015;149:128–37.PubMedCrossRef

160.

Sasso CV, Santiano FE, Arboccó FCV, Zyla LE, Semino SN, Guerrero-Gimenez ME, Creydt VP, Fontana CML, Carón RW. Estradiol and progesterone regulate proliferation and apoptosis in colon cancer. Endocr Connect. 2019;8:217–29.PubMedPubMedCentralCrossRef

161.

Bulzomi P, Galluzzo P, Bolli A, Leone S, Acconcia F, Marino M. The pro-apoptotic effect of quercetin in cancer cell lines requires ERbeta-dependent signals. J Cell Physiol. 2012;227:1891–8. https://doi.org/10.1002/jcp.22917.CrossRefPubMed

162.

Sanaei M, Kavoosi F. Effect of 5-aza-2′-deoxycytidine on estrogen receptor alpha/beta and DNA methyltransferase 1 genes expression, apoptosis induction, and cell growth prevention of the colon cancer HT 29 cell line. Int J Prev Med. 2020;11:147. https://doi.org/10.4103/ijpvm.IJPVM_140_19.CrossRefPubMedPubMedCentral

163.

Edvardsson K, Strom A, Jonsson P, Gustafsson JA, Williams C. Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol. 2011;25:969–79. https://doi.org/10.1210/me.2010-0452.CrossRefPubMedPubMedCentral

164.

Bernatchez G, Giroux V, Lassalle T, Carpentier AC, Rivard N, Carrier JC. ERRα metabolic nuclear receptor controls growth of colon cancer cells. Carcinogenesis. 2013;34:2253–61.PubMedCrossRef

165.

Mencarelli A, Distrutti E, Renga B, D’Amore C, Cipriani S, Palladino G, Donini A, Ricci P, Fiorucci S. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS ONE. 2011;6:e22978. https://doi.org/10.1371/journal.pone.0022978.ADSCrossRefPubMedPubMedCentral

166.

Mao J, Chen X, Wang C, Li W, Li J. Effects and mechanism of the bile acid (farnesoid X) receptor on the Wnt/beta-catenin signaling pathway in colon cancer. Oncol Lett. 2020;20:337–45. https://doi.org/10.3892/ol.2020.11545.CrossRefPubMedPubMedCentral

167.

Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther. 2009;328:469–77.PubMedCrossRef

168.

Peng Z, Raufman J-P, Xie G. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PLoS ONE. 2012;7:e48461.ADSPubMedPubMedCentralCrossRef

169.

Yang F, Hu Y, Liu H-X, Wan Y-JY. MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem. 2015;290:6507–15.PubMedPubMedCentralCrossRef

170.

Hotta M, Sakatani T, Ishino K, Wada R, Kudo M, Yokoyama Y, Yamada T, Yoshida H, Naito Z. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5. Biochem Biophys Res Commun. 2019;519:824–31.PubMedCrossRef

171.

Selmin OI, Fang C, Lyon AM, Doetschman TC, Thompson PA, Martinez JD, Smith JW, Lance PM, Romagnolo DF. Inactivation of adenomatous polyposis coli reduces bile acid/farnesoid X receptor expression through Fxr gene CpG methylation in mouse colon tumors and human colon cancer cells. J Nutr. 2016;146:236–42.PubMedCrossRef

172.

Qiao P, Li S, Zhang H, Yao L, Wang F. Farnesoid X receptor inhibits proliferation of human colorectal cancer cells via the miR-135A1/CCNG2 signaling pathway. Oncol Rep. 2018;40:2067–78.PubMed

173.

Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Can Res. 2008;68:9589–94.CrossRef

174.

Peng Z, Chen J, Drachenberg CB, Raufman J-P, Xie G. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer. J Biol Chem. 2019;294:8529–42.PubMedPubMedCentralCrossRef

175.

Xu T, Wu K, Zhang L, Zheng S, Wang X, Zuo H, Wu X, Tao G, Jiang B, Zhang L. Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4alpha and WNK2 regulation. Cell Oncol (Dordr). 2020;43:297–310. https://doi.org/10.1007/s13402-019-00490-8.CrossRefPubMed

176.

Vuong LM, Chellappa K, Dhahbi JM, Deans JR, Fang B, Bolotin E, Titova NV, Hoverter NP, Spindler SR, Waterman ML, et al. Differential effects of hepatocyte nuclear factor 4alpha Isoforms on tumor growth and T-cell factor 4/AP-1 interactions in human colorectal cancer cells. Mol Cell Biol. 2015;35:3471–90. https://doi.org/10.1128/MCB.00030-15.CrossRefPubMedPubMedCentral

177.

Algamas-Dimantov A, Yehuda-Shnaidman E, Peri I, Schwartz B. Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy. Cell Oncol. 2013;36:155–67.CrossRef

178.

Lai HT, Chiang CT, Tseng WK, Chao TC, Su Y. GATA6 enhances the stemness of human colon cancer cells by creating a metabolic symbiosis through upregulating LRH-1 expression. Mol Oncol. 2020;14:1327–47. https://doi.org/10.1002/1878-0261.12647.CrossRefPubMedPubMedCentral

179.

Bayrer JR, Mukkamala S, Sablin EP, Webb P, Fletterick RJ. Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs. Proc Natl Acad Sci U S A. 2015;112:2467–72. https://doi.org/10.1073/pnas.1500978112.ADSCrossRefPubMedPubMedCentral

180.

Yuan Q, Cao G, Li J, Zhang Y, Yang W. MicroRNA-136 inhibits colon cancer cell proliferation and invasion through targeting liver receptor homolog-1/Wnt signaling. Gene. 2017;628:48–55. https://doi.org/10.1016/j.gene.2017.07.031.CrossRefPubMed

181.

Liang Y, Zhao Q, Fan L, Zhang Z, Tan B, Liu Y, Li Y. Down-regulation of MicroRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1. Biomed Pharmacother. 2015;75:137–41. https://doi.org/10.1016/j.biopha.2015.07.020.CrossRefPubMed

182.

Benod C, Carlsson J, Uthayaruban R, Hwang P, Irwin JJ, Doak AK, Shoichet BK, Sablin EP, Fletterick RJ. Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem. 2013;288:19830–44. https://doi.org/10.1074/jbc.M112.411686.CrossRefPubMedPubMedCentral

183.

Lai HT, Tseng WK, Huang SW, Chao TC, Su Y. MicroRNA-203 diminishes the stemness of human colon cancer cells by suppressing GATA6 expression. J Cell Physiol. 2020;235:2866–80. https://doi.org/10.1002/jcp.29192.CrossRefPubMed

184.

Schoonjans K, Dubuquoy L, Mebis J, Fayard E, Wendling O, Haby C, Geboes K, Auwerx J. Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation. Proc Natl Acad Sci U S A. 2005;102:2058–62. https://doi.org/10.1073/pnas.0409756102.ADSCrossRefPubMedPubMedCentral

185.

Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, et al. Intestinal steroidogenesis controls PPARgamma expression in the colon and is impaired during ulcerative colitis. Gut. 2015;64:901–10. https://doi.org/10.1136/gutjnl-2014-307618.CrossRefPubMed

186.

Kramer HB, Lai CF, Patel H, Periyasamy M, Lin ML, Feller SM, Fuller-Pace FV, Meek DW, Ali S, Buluwela L. LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner. Nucleic Acids Res. 2016;44:582–94. https://doi.org/10.1093/nar/gkv948.CrossRefPubMed

187.

Dianat-Moghadam H, Khalili M, Keshavarz M, Azizi M, Hamishehkar H, Rahbarghazi R, Nouri M. Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells in vitro. Cancer Cell Int. 2021;21:100. https://doi.org/10.1186/s12935-021-01803-4.CrossRefPubMedPubMedCentral

188.

Courtaut F, Derangere V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rebe C. Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRbeta subcellular localization. Oncotarget. 2015;6:26651–62. https://doi.org/10.18632/oncotarget.5791.CrossRefPubMedPubMedCentral

189.

Tang H, Mirshahidi S, Senthil M, Kazanjian K, Chen CS, Zhang K. Down-regulation of LXR/RXR activation and negative acute phase response pathways in colon adenocarcinoma revealed by proteomics and bioinformatics analysis. Cancer Biomark. 2014;14:313–24. https://doi.org/10.3233/CBM-140409.CrossRefPubMed

190.

Derangere V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Vegran F, Ladoire S, et al. Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ. 2014;21:1914–24. https://doi.org/10.1038/cdd.2014.117.CrossRefPubMedPubMedCentral

191.

Vedin LL, Gustafsson JA, Steffensen KR. The oxysterol receptors LXRalpha and LXRbeta suppress proliferation in the colon. Mol Carcinog. 2013;52:835–44. https://doi.org/10.1002/mc.21924.CrossRefPubMed

192.

Uno S, Endo K, Jeong Y, Kawana K, Miyachi H, Hashimoto Y, Makishima M. Suppression of beta-catenin signaling by liver X receptor ligands. Biochem Pharmacol. 2009;77:186–95. https://doi.org/10.1016/j.bcp.2008.10.007.CrossRefPubMed

193.

Nguyen TTT, Ishida CT, Shang E, Shu C, Torrini C, Zhang Y, Bianchetti E, Sanchez-Quintero MJ, Kleiner G, Quinzii CM, et al. Activation of LXRbeta inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition. EMBO Mol Med. 2019;11: e10769. https://doi.org/10.15252/emmm.201910769.CrossRefPubMedPubMedCentral

194.

Wang Q, Ren M, Feng F, Chen K, Ju X. Treatment of colon cancer with liver X receptor agonists induces immunogenic cell death. Mol Carcinog. 2018;57:903–10. https://doi.org/10.1002/mc.22811.CrossRefPubMed

195.

Warns J, Marwarha G, Freking N, Ghribi O. 27-hydroxycholesterol decreases cell proliferation in colon cancer cell lines. Biochimie. 2018;153:171–80. https://doi.org/10.1016/j.biochi.2018.07.006.CrossRefPubMedPubMedCentral

196.

Hu Y, French SW, Chau T, Liu HX, Sheng L, Wei F, Stondell J, Garcia JC, Du Y, Bowlus CL, et al. RARbeta acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. FASEB J. 2019;33:2314–26. https://doi.org/10.1096/fj.201801390R.CrossRefPubMed

197.

Cho SD, Lei P, Abdelrahim M, Yoon K, Liu S, Guo J, Papineni S, Chintharlapalli S, Safe S. 1,1-bis(3′-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells. Mol Carcinog. 2008;47:252–63. https://doi.org/10.1002/mc.20378.CrossRefPubMed

198.

To SK, Zeng WJ, Zeng JZ, Wong AS. Hypoxia triggers a Nur77-beta-catenin feed-forward loop to promote the invasive growth of colon cancer cells. Br J Cancer. 2014;110:935–45. https://doi.org/10.1038/bjc.2013.816.CrossRefPubMedPubMedCentral

199.

Lee SO, Li X, Hedrick E, Jin UH, Tjalkens RB, Backos DS, Li L, Zhang Y, Wu Q, Safe S. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells. Mol Endocrinol. 2014;28:1729–39. https://doi.org/10.1210/me.2014-1102.CrossRefPubMedPubMedCentral

200.

Kang HJ, Song MJ, Choung SY, Kim SJ, Le MO. Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull. 2000;23:815–9. https://doi.org/10.1248/bpb.23.815.CrossRefPubMed

201.

Hedrick E, Lee SO, Safe S. The nuclear orphan receptor NR4A1 regulates beta1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists. Mol Carcinog. 2017;56:2066–75. https://doi.org/10.1002/mc.22662.CrossRefPubMedPubMedCentral

202.

Hu Y, Chau T, Liu H-X, Liao D, Keane R, Nie Y, Yang H, Wan Y-JY. Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis. Mol Cancer Res. 2015;13:281–92.PubMedCrossRef

203.

Lei P, Abdelrahim M, Cho SD, Liu S, Chintharlapalli S, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis. 2008;29:1139–47. https://doi.org/10.1093/carcin/bgn103.CrossRefPubMedPubMedCentral

204.

Holla VR, Wu H, Shi Q, Menter DG, DuBois RN. Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem. 2011;286:30003–9. https://doi.org/10.1074/jbc.M110.184697.CrossRefPubMedPubMedCentral

205.

Abdel-Latif RT, Wadie W, Abdel-Mottaleb Y, Abdallah DM, El-Maraghy NN, El-Abhar HS. Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model. Saudi Pharm J. 2022;30:72–90. https://doi.org/10.1016/j.jsps.2021.12.009.CrossRefPubMed

206.

Lachal S, Ford J, Shulkes A, Baldwin GS. PPARα agonists stimulate progastrin production in human colorectal carcinoma cells. Regul Pept. 2004;120:243–51.PubMedCrossRef

207.

Grau R, Iñiguez MA, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Δ12, 14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-γ-independent mechanism. Can Res. 2004;64:5162–71.CrossRef

208.

Kohno H, Yoshitani Si, Takashima S, Okumura A, Hosokawa M, Yamaguchi N, Tanaka T. Troglitazone, a Ligand for Peroxisome Proliferator-activated Receptor γ Inhibits Chemically-induced Aberrant Crypt Foci in Rats. Jpn J Cancer Res. 2001;92:396–403.PubMedPubMedCentralCrossRef

209.

Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem. 2001;276:29681–7.PubMedCrossRef

210.

Su W, Necela BM, Fujiwara K, Kurakata S, Murray NR, Fields AP, Thompson EA. The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int J Cancer. 2008;123:991–7. https://doi.org/10.1002/ijc.23640.CrossRefPubMedPubMedCentral

211.

Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis. 2007;8:82–8.PubMedCrossRef

212.

Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI, Kim WH. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer. 2014;134:519–29.PubMedCrossRef

213.

Kohno H, Yasui Y, Suzuki R, Hosokawa M, Miyashita K, Tanaka T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARγ expression and alteration of lipid composition. Int J Cancer. 2004;110:896–901.PubMedCrossRef

214.

Wang J-B, Qi L-L, Zheng S-D, Wang H-Z, Wu T-X. Curcumin suppresses PPARδ expression and related genes in HT-29 cells. World J Gastroenterol: WJG. 2009;15:1346.PubMedPubMedCentralCrossRef

215.

Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, Song MJ, Han SB, Moon DC, Kang KW, et al. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010;188:75–85. https://doi.org/10.1016/j.cbi.2010.06.001.CrossRefPubMed

216.

Yang L, Zhou J, Ma Q, Wang C, Chen K, Meng W, Yu Y, Zhou Z, Sun X. Knockdown of PPAR delta gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PLoS ONE. 2013;8: e60715. https://doi.org/10.1371/journal.pone.0060715.ADSCrossRefPubMedPubMedCentral

217.

Jackson L, Wahli W, Michalik L, Watson SA, Morris T, Anderton K, Bell DR, Smith JA, Hawkey CJ, Bennett AJ. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut. 2003;52:1317–22. https://doi.org/10.1136/gut.52.9.1317.CrossRefPubMedPubMedCentral

218.

Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD, Ran ZH. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585:3560–8. https://doi.org/10.1016/j.febslet.2011.10.021.CrossRefPubMed

219.

Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ. Isoform specific changes in PPAR alpha and beta in colon and breast cancer with differentiation. Biochem Biophys Res Commun. 2006;340:656–60. https://doi.org/10.1016/j.bbrc.2005.12.061.CrossRefPubMed

220.

Zhou D, Jin J, Liu Q, Shi J, Hou Y. PPARδ agonist enhances colitis-associated colorectal cancer. Eur J Pharmacol. 2019;842:248–54. https://doi.org/10.1016/j.ejphar.2018.10.050.CrossRefPubMed

221.

Yang W-L, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22:1379–83.PubMedCrossRef

222.

Campbell SE, Stone WL, Whaley SG, Qui M, Krishnan K. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer. 2003;3:25. https://doi.org/10.1186/1471-2407-3-25.CrossRefPubMedPubMedCentral

223.

Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol. 2004;25:631–9.PubMed

224.

Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho S-d, Murthy RS, You Y, Safe S. 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells. Carcinogenesis. 2007;28:2337–46.PubMedCrossRef

225.

Shen D, Deng C, Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J. 2007;83:414–9. https://doi.org/10.1136/pmj.2006.052761.CrossRefPubMedPubMedCentral

226.

Choi IK, Kim YH, Kim JS, Seo JH. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Invest New Drugs. 2008;26:283–8. https://doi.org/10.1007/s10637-007-9108-x.CrossRefPubMed

227.

Dai Y, Qiao L, Chan KW, Zou B, Ma J, Lan HY, Gu Q, Li Z, Wang Y, Wong BL, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer. 2008;122:2858–63. https://doi.org/10.1002/ijc.23443.CrossRefPubMed

228.

Rageul J, Mottier S, Jarry A, Shah Y, Théoleyre S, Masson D, Gonzalez FJ, Laboisse CL, Denis MG. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer. 2009;125:2802–9. https://doi.org/10.1002/ijc.24683.CrossRefPubMedPubMedCentral

229.

Tsukahara T, Haniu H, Matsuda Y. PTB-associated splicing factor (PSF) is a PPARγ-binding protein and growth regulator of colon cancer cells. PLoS ONE. 2013;8: e58749.ADSPubMedPubMedCentralCrossRef

230.

Tylichová Z, Straková N, Vondráček J, Vaculová AH, Kozubík A, Hofmanová J. Activation of autophagy and PPARγ protect colon cancer cells against apoptosis induced by interactive effects of butyrate and DHA in a cell type-dependent manner: The role of cell differentiation. J Nutr Biochem. 2017;39:145–55. https://doi.org/10.1016/j.jnutbio.2016.09.006.CrossRefPubMed

231.

Yaacob NS, Darus HM, Norazmi MN. Modulation of cell growth and PPARγ expression in human colorectal cancer cell lines by ciglitazone. Exp Toxicol Pathol. 2008;60:505–12.PubMedCrossRef

232.

Lee JY, Hwang DH. Docosahexaenoic acid suppresses the activity of peroxisome proliferator-activated receptors in a colon tumor cell line. Biochem Biophys Res Commun. 2002;298:667–74. https://doi.org/10.1016/s0006-291x(02)02530-5.CrossRefPubMed

233.

Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361–7. https://doi.org/10.1053/gast.2003.50067.CrossRefPubMed

234.

Weidner C, Rousseau M, Micikas RJ, Fischer C, Plauth A, Wowro SJ, Siems K, Hetterling G, Kliem M, Schroeder FC. Amorfrutin C induces apoptosis and inhibits proliferation in colon cancer cells through targeting mitochondria. J Nat Prod. 2016;79:2–12.PubMedCrossRef

235.

Mielczarek-Puta M, Otto-Slusarczyk D, Chrzanowska A, Filipek A, Grabon W. Telmisartan influences the antiproliferative activity of linoleic acid in human colon cancer cells. Nutr Cancer. 2020;72:98–109. https://doi.org/10.1080/01635581.2019.1613552.CrossRefPubMed

236.

Papi A, Rocchi P, Ferreri AM, Orlandi M. RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett. 2010;297:65–74.PubMedCrossRef

237.

Bansard L, Bouvet O, Moutin E, Le Gall G, Giammona A, Pothin E, Bacou M, Hassen-Khodja C, Bordignon B, Bourgaux JF. Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy. Stem Cell Reports. 2022;17:835–48.PubMedPubMedCentralCrossRef

238.

Planque C, Rajabi F, Grillet F, Finetti P, Bertucci F, Gironella M, Lozano JJ, Beucher B, Giraud J, Garambois V. Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. Oncotarget. 2016;7:56558.PubMedPubMedCentralCrossRef

239.

Cheng J, Fang Z-Z, Nagaoka K, Okamoto M, Qu A, Tanaka N, Kimura S, Gonzalez FJ. Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer. J Pharmacol Exp Ther. 2014;351:559–67.PubMedPubMedCentralCrossRef

240.

Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, Schinkel AH. PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009;36:565–71.PubMedCrossRef

241.

Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010;335:32–41.PubMedPubMedCentralCrossRef

242.

Dou W, Mukherjee S, Li H, Venkatesh M, Wang H, Kortagere S, Peleg A, Chilimuri SS, Wang Z-T, Feng Y. Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS ONE. 2012;7:e36075.ADSPubMedPubMedCentralCrossRef

243.

Liu C-L, Lim Y-P, Hu M-L. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs. 2012;10:242–57.PubMedPubMedCentralCrossRef

244.

Esposito G, Gigli S, Seguella L, Nobile N, D’alessandro A, Pesce M, Capoccia E, Steardo L, Cirillo C, Cuomo R. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016;49:639–45.PubMedCrossRef

245.

Harmsen S, Meijerman I, Febus C, Maas-Bakker R, Beijnen J, Schellens J. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010;66:765–71.PubMedCrossRef

246.

Habano W, Gamo T, Terashima J, Sugai T, Otsuka K, Wakabayashi G, Ozawa S. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer. 2011;11:1–10.CrossRef

247.

Kuo CT, Lee WS. Progesterone receptor activation is required for folic acid-induced anti-proliferation in colorectal cancer cell lines. Cancer Lett. 2016;378:104–10. https://doi.org/10.1016/j.canlet.2016.05.019.CrossRefPubMed

248.

Cesario RM, Stone J, Yen W-C, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR: PPARγ heterodimer in colon cancer. Cancer Lett. 2006;240:225–33.PubMedCrossRef

249.

Dillard AC, Lane MA. Retinol decreases β-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog. 2007;46:315–29.PubMedCrossRef

250.

Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis. 2003;24:1541–8. https://doi.org/10.1093/carcin/bgg110.CrossRefPubMed

251.

Janakiram NB, Mohammed A, Qian L, Choi C-I, Steele VE, Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of ApcMin/+ mice. Neoplasia. 2012;14:159–68.PubMedPubMedCentralCrossRef

252.

Ruan H, Zhan Y, Hou J, Xu B, Chen B, Tian Y, Wu D, Zhao Y, Zhang Y, Chen X. Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells. Oncogene. 2017;36:6906–18.PubMedPubMedCentralCrossRef

253.

Xu B, Jiang X, Xiong J, Lan J, Tian Y, Zhong L, Wang X, Xu N, Cao H, Zhang W. Structure–activity relationship study enables the discovery of a novel berberine analogue as the RXRα activator to inhibit colon cancer. J Med Chem. 2020;63:5841–55.PubMedCrossRef

254.

Papi A, Ferreri A, Guerra F, Orlandi M. Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines. Anticancer Res. 2012;32:2855–62.PubMed

255.

Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, Nishiyama K, Nagayama K, Misawa H, Masuda H, et al. Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun. 2003;309:408–13. https://doi.org/10.1016/j.bbrc.2003.08.019.CrossRefPubMed

256.

Pourvali K, Shimi G, Ghorbani A, Shakery A, Shirazi FH, Zand H. Selective thyroid hormone receptor beta agonist, GC-1, is capable to reduce growth of colorectal tumor in syngeneic mouse models. J Recept Signal Transduct Res. 2022;42:495–502. https://doi.org/10.1080/10799893.2022.2032748.CrossRefPubMed

257.

Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6:1433–9. https://doi.org/10.1158/1535-7163.MCT-06-0677.CrossRefPubMed

258.

Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Munoz A, Jimenez B. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 2005;24:6533–44. https://doi.org/10.1038/sj.onc.1208801.CrossRefPubMed

259.

Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol. 2012;26:37–51. https://doi.org/10.1210/me.2011-1109.CrossRefPubMed

260.

Ranji P, Agah S, Heydari Z, Rahmati-Yamchi M, Mohammad Alizadeh A. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the serum biochemical parameters, and the vitamin D and leptin receptor genes on mice colon cancer. Iran J Basic Med Sci. 2019;22:631–6. https://doi.org/10.22038/ijbms.2019.32624.7806.CrossRefPubMedPubMedCentral

261.

Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154:369–87. https://doi.org/10.1083/jcb.200102028.CrossRefPubMedPubMedCentral

262.

Donohue MM, Demay MB. Rickets in VDR null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology. 2002;143:3691–4. https://doi.org/10.1210/en.2002-220454.CrossRefPubMed

263.

Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis. 2001;22:1429–35. https://doi.org/10.1093/carcin/22.9.1429.CrossRefPubMed

264.

Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217–24. https://doi.org/10.1002/eji.200425491.CrossRefPubMed

265.

Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, Ishiguro S. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer. 1999;81:730–3. https://doi.org/10.1002/(sici)1097-0215(19990531)81:5%3c730::aid-ijc11%3e3.0.co;2-q.CrossRefPubMed

266.

Chen S, Bu D, Ma Y, Zhu J, Chen G, Sun L, Zuo S, Li T, Pan Y, Wang X, et al. H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells. Neoplasia. 2017;19:226–36. https://doi.org/10.1016/j.neo.2016.10.007.CrossRefPubMedPubMedCentral

267.

Zhang Y, Garrett S, Carroll RE, Xia Y, Sun J. Vitamin D receptor upregulates tight junction protein claudin-5 against colitis-associated tumorigenesis. Mucosal Immunol. 2022;15:683–97. https://doi.org/10.1038/s41385-022-00502-1.CrossRefPubMedPubMedCentral

268.

Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A, Palmer HG. Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS ONE. 2011;6: e23524. https://doi.org/10.1371/journal.pone.0023524.ADSCrossRefPubMedPubMedCentral

269.

Ishizawa M, Hirayu A, Makishima M. Zinc Inhibits Cadherin 1 Expression Induced by 1α, 25-Dihydroxyvitamin D3 in Colon Cancer Cells. Anticancer Res. 2021;41:5453–9.PubMedCrossRef

270.

Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun. 2002;299:730–8.PubMedCrossRef

271.

Egan JB, Thompson PA, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, Gerner EW, Jurutka PW. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate β-catenin activity in colon cancer cells. Mol Carcinog. 2010;49:337–52.PubMedPubMedCentralCrossRef

272.

Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, Hernandez Z, Haussler CA, Haussler MR, Jurutka PW. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem. 2010;21:1153–61.PubMedPubMedCentralCrossRef

273.

Qi X, Tang J, Pramanik R, Schultz RM, Shirasawa S, Sasazuki T, Han J, Chen G. p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem. 2004;279:22138–44.PubMedCrossRef

274.

Beildeck ME, Islam M, Shah S, Welsh J, Byers SW. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS ONE. 2009;4: e7872.ADSPubMedPubMedCentralCrossRef

275.

Chua FY, Adams BD. Androgen receptor and miR-206 regulation in prostate cancer. Transcription. 2017;8:313–27. https://doi.org/10.1080/21541264.2017.1322668.CrossRefPubMedPubMedCentral

276.

Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ. Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev. 2013;65:710–78. https://doi.org/10.1124/pr.112.006833.CrossRefPubMed

277.

Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016;37:3–15.PubMedPubMedCentral

278.

Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. https://doi.org/10.1126/science.1260419.CrossRefPubMed

279.

Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020. https://doi.org/10.3390/cells9122653.CrossRefPubMedPubMedCentral

280.

Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Can Res. 2005;65:8487–96.CrossRef

281.

Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124:607–17.PubMedCrossRef

282.

Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62–5.PubMedCrossRef

283.

Lønning PE. Additive endocrine therapy for advanced breast cancer–back to the future. Acta Oncol. 2009;48:1092–101.PubMedCrossRef

284.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Can Res. 2009;69:6131–40.CrossRef

285.

Izbicki JR, Wambach G, Hamilton SR, Harnisch E, Hogenschurz R, Izbicki W, Kusche J. Androgen receptors in experimentally induced colon carcinogenesis. J Cancer Res Clin Oncol. 1986;112:39–46. https://doi.org/10.1007/BF00394937.CrossRefPubMed

286.

Li H, Kim JH, Koh SS, Stallcup MR. Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem. 2004;279:4212–20. https://doi.org/10.1074/jbc.M311374200.CrossRefPubMed

287.

Song LN, Gelmann EP. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem. 2005;280:37853–67. https://doi.org/10.1074/jbc.M503850200.CrossRefPubMed

288.

Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking beta-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:11336–44. https://doi.org/10.1074/jbc.M111962200.CrossRefPubMed

289.

Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem. 2002;277:17933–43. https://doi.org/10.1074/jbc.M200135200.CrossRefPubMed

290.

Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene. 2002;21:8453–69. https://doi.org/10.1038/sj.onc.1206049.CrossRefPubMed

291.

Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4–2 cells. Oncogene. 2008;27:3596–604. https://doi.org/10.1038/sj.onc.1211016.CrossRefPubMedPubMedCentral

292.

Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res. 2011;71:862–72. https://doi.org/10.1158/0008-5472.CAN-10-1605.CrossRefPubMed

293.

Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406–17. https://doi.org/10.1093/emboj/19.20.5406.CrossRefPubMedPubMedCentral

294.

Ferro P, Catalano MG, Raineri M, Reato G, dell’Eva R, Risio M, Foa R, Fortunati N, Pfeffer U. Somatic alterations of the androgen receptor CAG repeat in human colon cancer delineate a novel mutation pathway independent of microsatellite instability. Cancer Genet Cytogenet. 2000;123:35–40. https://doi.org/10.1016/s0165-4608(00)00296-x.CrossRefPubMed

295.

Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD, Wolff R. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer. 2006;118:3140–6. https://doi.org/10.1002/ijc.21791.CrossRefPubMed

296.

Kim K, Kumagai J, Eishi Y, Ishige I, Ishige Y, Koike M. Clonality analysis for normal and cancerous colon tissues with human androgen receptor gene polymerase chain reaction. J Med Dent Sci. 2005;52:163–70.PubMed

297.

Xia T, Sun H, Huang H, Bi H, Pu R, Zhang L, Zhang Y, Liu Y, Xu J, Onwuka JU, et al. Androgen receptor gene methylation related to colorectal cancer risk. Endocr Connect. 2019;8:979–87. https://doi.org/10.1530/EC-19-0122.CrossRefPubMedPubMedCentral

298.

Klepsch V, Siegmund K, Baier G. Emerging next-generation target for cancer immunotherapy research: the orphan nuclear receptor NR2F6. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13112600.CrossRefPubMed

299.

Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen receptor function: impact on the human endometrium. Front Endocrinol (Lausanne). 2022;13: 827724. https://doi.org/10.3389/fendo.2022.827724.CrossRefPubMed

300.

Bharathkumar H, Mohan CD, Ananda H, Fuchs JE, Li F, Rangappa S, Surender M, Bulusu KC, Girish KS, Sethi G. Microwave-assisted synthesis, characterization and cytotoxic studies of novel estrogen receptor α ligands towards human breast cancer cells. Bioorg Med Chem Lett. 2015;25:1804–7.PubMedCrossRef

301.

Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7:497–508. https://doi.org/10.2174/138920206779315737.CrossRefPubMedPubMedCentral

302.

Jia M, Dahlman-Wright K, Gustafsson JA. Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29:557–68. https://doi.org/10.1016/j.beem.2015.04.008.CrossRefPubMed

303.

Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERalpha) and beta (ERbeta): subtype-selective ligands and clinical potential. Steroids. 2014;90:13–29. https://doi.org/10.1016/j.steroids.2014.06.012.CrossRefPubMed

304.

Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006;147:4831–42. https://doi.org/10.1210/en.2006-0563.CrossRefPubMed

305.

Indukuri R, Hases L, Archer A, Williams C. Estrogen receptor beta influences the inflammatory p65 cistrome in colon cancer cells. Front Endocrinol (Lausanne). 2021;12: 650625. https://doi.org/10.3389/fendo.2021.650625.CrossRefPubMed

306.

Macdonald RS, Wagner K. Influence of dietary phytochemicals and microbiota on colon cancer risk. J Agric Food Chem. 2012;60:6728–35. https://doi.org/10.1021/jf204230r.CrossRefPubMed

307.

Berner C, Aumüller E, Gnauck A, Nestelberger M, Just A, Haslberger AG. Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Ann Nutr Metab. 2010;57:183–9.PubMedCrossRef

308.

Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer. 2006;13(Suppl 1):S25-32. https://doi.org/10.1677/erc.1.01292.CrossRefPubMed

309.

Tripathi M, Yen PM, Singh BK. Estrogen-related receptor alpha: an under-appreciated potential target for the treatment of metabolic diseases. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21051645.CrossRefPubMedPubMedCentral

310.

Vernier M, Dufour CR, McGuirk S, Scholtes C, Li X, Bourmeau G, Kuasne H, Park M, St-Pierre J, Audet-Walsh E, et al. Estrogen-related receptors are targetable ROS sensors. Genes Dev. 2020;34:544–59. https://doi.org/10.1101/gad.330746.119.CrossRefPubMedPubMedCentral

311.

Ranhotra HS. Estrogen-related receptor alpha and cancer: axis of evil. J Recept Signal Transduct Res. 2015;35:505–8. https://doi.org/10.3109/10799893.2015.1049362.CrossRefPubMed

312.

Ding S, Tang Z, Jiang Y, Huang H, Luo P, Qing B, Zhang S, Tang R. IL-8 is involved in estrogen-related receptor alpha-regulated proliferation and migration of colorectal cancer cells. Dig Dis Sci. 2017;62:3438–46. https://doi.org/10.1007/s10620-017-4779-4.CrossRefPubMed

313.

Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005;48:5383–403. https://doi.org/10.1021/jm0582221.CrossRefPubMed

314.

Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–43. https://doi.org/10.1002/hep.22519.CrossRefPubMed

315.

Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyotylainen T, Oresic M, Backhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17:225–35. https://doi.org/10.1016/j.cmet.2013.01.003.CrossRefPubMed

316.

Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788–801. https://doi.org/10.1002/hep.30509.CrossRefPubMed

317.

Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): structures and ligands. Comput Struct Biotechnol J. 2021;19:2148–59. https://doi.org/10.1016/j.csbj.2021.04.029.CrossRefPubMedPubMedCentral

318.

Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76:1221–6. https://doi.org/10.1007/s40265-016-0616-x.CrossRefPubMed

319.

You W, Chen B, Liu X, Xue S, Qin H, Jiang H. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 2017;7:591. https://doi.org/10.1038/s41598-017-00698-4.ADSCrossRefPubMedPubMedCentral

320.

Giaginis C, Tsoukalas N, Alexandrou P, Tsourouflis G, Dana E, Delladetsima I, Patsouris E, Theocharis S. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13:1785–92. https://doi.org/10.2217/fon-2017-0090.CrossRefPubMed

321.

Giaginis C, Karandrea D, Alexandrou P, Giannopoulou I, Tsourouflis G, Troungos C, Danas E, Keramopoulos A, Patsouris E, Nakopoulou L, et al. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma. Neoplasma. 2017;64:633–9. https://doi.org/10.4149/neo_2017_420.CrossRefPubMed

322.

Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313–42.PubMedPubMedCentralCrossRef

323.

Yeh MM, Bosch DE, Daoud SS. Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases. World J Gastroenterol. 2019;25:4074–91. https://doi.org/10.3748/wjg.v25.i30.4074.CrossRefPubMedPubMedCentral

324.

Sun Q, Xu W, Ji S, Qin Y, Liu W, Hu Q, Zhang Z, Liu M, Yu X, Xu X. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell Int. 2019;19:49. https://doi.org/10.1186/s12935-019-0767-4.CrossRefPubMedPubMedCentral

325.

Lv DD, Zhou LY, Tang H. Hepatocyte nuclear factor 4alpha and cancer-related cell signaling pathways: a promising insight into cancer treatment. Exp Mol Med. 2021;53:8–18. https://doi.org/10.1038/s12276-020-00551-1.CrossRefPubMedPubMedCentral

326.

Wu N, Zhang YL, Wang HT, Li DW, Dai HJ, Zhang QQ, Zhang J, Ma Y, Xia Q, Bian JM, et al. Overexpression of hepatocyte nuclear factor 4alpha in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/beta-catenin signaling pathway downregulation. Cancer Biol Ther. 2016;17:558–65. https://doi.org/10.1080/15384047.2016.1177675.CrossRefPubMedPubMedCentral

327.

Ma L, Zeng J, Guo Q, Liang X, Shen L, Li S, Sun Y, Li W, Liu S, Yu H, et al. Mutual amplification of HNF4alpha and IL-1R1 composes an inflammatory circuit in Helicobacter pylori associated gastric carcinogenesis. Oncotarget. 2016;7:11349–63. https://doi.org/10.18632/oncotarget.7239.CrossRefPubMedPubMedCentral

328.

Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest. 1998;102:1385–92. https://doi.org/10.1172/JCI3785.CrossRefPubMedPubMedCentral

329.

Yang YM, Lee CG, Koo JH, Kim TH, Lee JM, An J, Kim KM, Kim SG. Galpha12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4alpha inactivation, which causes c-Met induction. Oncotarget. 2015;6:19055–69. https://doi.org/10.18632/oncotarget.3957.CrossRefPubMedPubMedCentral

330.

Darsigny M, Babeu JP, Dupuis AA, Furth EE, Seidman EG, Levy E, Verdu EF, Gendron FP, Boudreau F. Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS ONE. 2009;4:e7609. https://doi.org/10.1371/journal.pone.0007609.ADSCrossRefPubMedPubMedCentral

331.

Saandi T, Baraille F, Derbal-Wolfrom L, Cattin AL, Benahmed F, Martin E, Cardot P, Duclos B, Ribeiro A, Freund JN, et al. Regulation of the tumor suppressor homeogene Cdx2 by HNF4alpha in intestinal cancer. Oncogene. 2013;32:3782–8. https://doi.org/10.1038/onc.2012.401.CrossRefPubMed

332.

Pervin M, Paeng N, Yasui K, Imai S, Isemura M, Yokogoshi H, Nakayama T. Effects of Lens culinaris agglutinin on gene expression of gluconeogenic enzymes in the mouse intestine. J Sci Food Agric. 2012;92:857–61. https://doi.org/10.1002/jsfa.4658.CrossRefPubMed

333.

Chellappa K, Deol P, Evans JR, Vuong LM, Chen G, Briancon N, Bolotin E, Lytle C, Nair MG, Sladek FM. Opposing roles of nuclear receptor HNF4alpha isoforms in colitis and colitis-associated colon cancer. Elife. 2016. https://doi.org/10.7554/eLife.10903.CrossRefPubMedPubMedCentral

334.

Nadolny C, Dong X. Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer. Cancer Biol Ther. 2015;16:997–1004. https://doi.org/10.1080/15384047.2015.1045693.CrossRefPubMedPubMedCentral

335.

Mays SG, Okafor CD, Tuntland ML, Whitby RJ, Dharmarajan V, Stec J, Griffin PR, Ortlund EA. Structure and Dynamics of the Liver Receptor Homolog 1-PGC1alpha Complex. Mol Pharmacol. 2017;92:1–11. https://doi.org/10.1124/mol.117.108514.CrossRefPubMedPubMedCentral

336.

Meinsohn MC, Smith OE, Bertolin K, Murphy BD. The orphan nuclear receptors steroidogenic factor-1 and liver receptor homolog-1: structure, regulation, and essential roles in mammalian reproduction. Physiol Rev. 2019;99:1249–79. https://doi.org/10.1152/physrev.00019.2018.CrossRefPubMed

337.

Sidler D, Renzulli P, Schnoz C, Berger B, Schneider-Jakob S, Fluck C, Inderbitzin D, Corazza N, Candinas D, Brunner T. Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene. 2011;30:2411–9. https://doi.org/10.1038/onc.2010.629.CrossRefPubMed

338.

Sidler D, Renzulli P, Schnoz C, Berger B, Schneider-Jakob S, Fluck C, Inderbitzin D, Corazza N, Candinas D, Brunner T. Colon cancer cells produce immunoregulatory glucocorticoids. Oncoimmunology. 2012;1:529–30. https://doi.org/10.4161/onci.19459.CrossRefPubMedPubMedCentral

339.

Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14:452–63. https://doi.org/10.1038/s41574-018-0037-x.CrossRefPubMedPubMedCentral

340.

Gao BC, Chen Q, Sun T, Wang DM, Xiao J. Research progress of the relationship between liver X receptor and inflammatory-related diseases. Sheng Li Xue Bao. 2018;70:335–41.PubMed

341.

Zhu R, Ou Z, Ruan X, Gong J. Role of liver X receptors in cholesterol efflux and inflammatory signaling (review). Mol Med Rep. 2012;5:895–900. https://doi.org/10.3892/mmr.2012.758.CrossRefPubMedPubMedCentral

342.

Bilotta MT, Petillo S, Santoni A, Cippitelli M. Liver X receptors: regulators of cholesterol metabolism, inflammation, autoimmunity, and cancer. Front Immunol. 2020;11:584303. https://doi.org/10.3389/fimmu.2020.584303.CrossRefPubMedPubMedCentral

343.

Lin CY, Gustafsson JA. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015;15:216–24. https://doi.org/10.1038/nrc3912.CrossRefPubMed

344.

Rebe C, Derangere V, Ghiringhelli F. Induction of pyroptosis in colon cancer cells by LXRbeta. Mol Cell Oncol. 2015;2:e970094. https://doi.org/10.4161/23723548.2014.970094.CrossRefPubMedPubMedCentral

345.

Sharma B, Gupta V, Dahiya D, Kumar H, Vaiphei K, Agnihotri N. Clinical relevance of cholesterol homeostasis genes in colorectal cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:1314–27. https://doi.org/10.1016/j.bbalip.2019.06.008.CrossRefPubMed

346.

Yun SH, Park MG, Kim YM, Roh MS, Park JI. Expression of chicken ovalbumin upstream promoter-transcription factor II and liver X receptor as prognostic indicators for human colorectal cancer. Oncol Lett. 2017;14:4011–20. https://doi.org/10.3892/ol.2017.6659.CrossRefPubMedPubMedCentral

347.

To SK, Zeng JZ, Wong AS. Nur77: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2012;16:573–85. https://doi.org/10.1517/14728222.2012.680958.CrossRefPubMed

348.

Wansa KD, Harris JM, Muscat GE. The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. J Biol Chem. 2002;277:33001–11. https://doi.org/10.1074/jbc.M203572200.CrossRefPubMed

349.

Chen HZ, Liu QF, Li L, Wang WJ, Yao LM, Yang M, Liu B, Chen W, Zhan YY, Zhang MQ, et al. The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling. Gut. 2012;61:714–24. https://doi.org/10.1136/gutjnl-2011-300783.CrossRefPubMed

350.

Niu B, Liu J, Lv B, Lin J, Li X, Wu C, Jiang X, Zeng Z, Zhang XK, Zhou H. Interplay between transforming growth factor-beta and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis. Nat Commun. 2021;12:2809. https://doi.org/10.1038/s41467-021-23048-5.ADSCrossRefPubMedPubMedCentral

351.

Sun Z, Cao X, Jiang MM, Qiu Y, Zhou H, Chen L, Qin B, Wu H, Jiang F, Chen J, et al. Inhibition of beta-catenin signaling by nongenomic action of orphan nuclear receptor Nur77. Oncogene. 2012;31:2653–67. https://doi.org/10.1038/onc.2011.448.CrossRefPubMed

352.

Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res. 2003;63:5401–7.PubMed

353.

Messmer K, Remington MP, Skidmore F, Fishman PS. Induction of tyrosine hydroxylase expression by the transcription factor Pitx3. Int J Dev Neurosci. 2007;25:29–37. https://doi.org/10.1016/j.ijdevneu.2006.11.003.CrossRefPubMed

354.

Grimm SL, Hartig SM, Edwards DP. Progesterone Receptor Signaling Mechanisms. J Mol Biol. 2016;428:3831–49. https://doi.org/10.1016/j.jmb.2016.06.020.CrossRefPubMed

355.

Sriraman V, Rudd MD, Lohmann SM, Mulders SM, Richards JS. Cyclic guanosine 5′-monophosphate-dependent protein kinase II is induced by luteinizing hormone and progesterone receptor-dependent mechanisms in granulosa cells and cumulus oocyte complexes of ovulating follicles. Mol Endocrinol. 2006;20:348–61. https://doi.org/10.1210/me.2005-0317.CrossRefPubMed

356.

Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur J Med Chem. 2019;166:502–13.PubMedCrossRef

357.

Wagner N, Wagner KD. The role of PPARs in disease. Cells. 2020. https://doi.org/10.3390/cells9112367.CrossRefPubMedPubMedCentral

358.

Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21062061.CrossRefPubMedPubMedCentral

359.

Strosznajder AK, Wójtowicz S, Jeżyna MJ, Sun GY, Strosznajder JB. Recent insights on the role of PPAR-β/δ in neuroinflammation and neurodegeneration, and its potential target for therapy. NeuroMol Med. 2021;23:86–98.CrossRef

360.

Wagner N, Wagner K-D. PPAR beta/delta and the hallmarks of cancer. Cells. 2020;9:1133.PubMedPubMedCentralCrossRef

361.

Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA, et al. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009;175:1270–80. https://doi.org/10.2353/ajpath.2009.081078.CrossRefPubMedPubMedCentral

362.

Garcia-Bates TM, Bernstein SH, Phipps RP. Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin Cancer Res. 2008;14:6414–25. https://doi.org/10.1158/1078-0432.CCR-08-0457.CrossRefPubMedPubMedCentral

363.

Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164:68–82. https://doi.org/10.1111/j.1476-5381.2011.01383.x.CrossRefPubMedPubMedCentral

364.

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4:1046–52.PubMedCrossRef

365.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, et al. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98:2392–400. https://doi.org/10.1210/jc.2013-1106.CrossRefPubMedPubMedCentral

366.

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012;118:5403–13. https://doi.org/10.1002/cncr.27526.CrossRefPubMed

367.

Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu A. Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New Drugs. 2014;32:473–80. https://doi.org/10.1007/s10637-013-0056-3.CrossRefPubMed

368.

Xing Y, Yan J, Niu Y. PXR: a center of transcriptional regulation in cancer. Acta Pharmaceutica Sinica B. 2020;10:197–206.PubMedCrossRef

369.

Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83:1112–26. https://doi.org/10.1016/j.bcp.2012.01.030.CrossRefPubMedPubMedCentral

370.

Skandalaki A, Sarantis P, Theocharis S. Pregnane X receptor (PXR) polymorphisms and cancer treatment. Biomolecules. 2021;11:1142.PubMedPubMedCentralCrossRef

371.

Garcia P, Lorenzo P, de Lera AR. Natural ligands of RXR receptors. Methods Enzymol. 2020;637:209–34. https://doi.org/10.1016/bs.mie.2020.02.006.CrossRefPubMed

372.

Wagner CE, Jurutka PW, Marshall PA, Heck MC. Retinoid X receptor selective agonists and their synthetic methods. Curr Top Med Chem. 2017;17:742–67. https://doi.org/10.2174/1568026616666160617091559.CrossRefPubMed

373.

Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, Jia L, Zhang J, Yang J, Chen G, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020;19:134. https://doi.org/10.1186/s12943-020-01256-9.CrossRefPubMedPubMedCentral

374.

Anyetei-Anum CS, Roggero VR, Allison LA. Thyroid hormone receptor localization in target tissues. J Endocrinol. 2018;237:R19–34. https://doi.org/10.1530/JOE-17-0708.CrossRefPubMedPubMedCentral

375.

Zhang ZZ, Chen Q, Kong CY, Li ZM, Wang LS. Circulating thyroid stimulating hormone receptor messenger RNA and differentiated thyroid cancer: a diagnostic meta-analysis. Oncotarget. 2017;8:6623–9. https://doi.org/10.18632/oncotarget.14251.CrossRefPubMed

376.

Yang YSH, Ko PJ, Pan YS, Lin HY, Whang-Peng J, Davis PJ, Wang K. Role of thyroid hormone-integrin alphavbeta3-signal and therapeutic strategies in colorectal cancers. J Biomed Sci. 2021;28:24. https://doi.org/10.1186/s12929-021-00719-5.CrossRefPubMedPubMedCentral

377.

Diaz Flaque MC, Cayrol MF, Sterle HA, Del Rosario Aschero M, Diaz Albuja JA, Isse B, Farias RN, Cerchietti L, Rosemblit C, Cremaschi GA. Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells. Oncotarget. 2019;10:3051–65. https://doi.org/10.18632/oncotarget.26890.CrossRefPubMedPubMedCentral

378.

Kato S. The function of vitamin D receptor in vitamin D action. J Biochem. 2000;127:717–22. https://doi.org/10.1093/oxfordjournals.jbchem.a022662.CrossRefPubMed

379.

Gnagnarella P, Raimondi S, Aristarco V, Johansson HA, Bellerba F, Corso F, Gandini S. Vitamin D receptor polymorphisms and cancer. Adv Exp Med Biol. 2020;1268:53–114. https://doi.org/10.1007/978-3-030-46227-7_4.CrossRefPubMed

380.

Fathi N, Ahmadian E, Shahi S, Roshangar L, Khan H, Kouhsoltani M, Dizaj SM, Sharifi S. Role of vitamin D and vitamin D receptor (VDR) in oral cancer. Biomed Pharmacother. 2019;109:391–401.PubMedCrossRef

381.

Jeon S-M, Shin E. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50:1–14.PubMed

382.

Dou R, Ng K, Giovannucci EL, Manson JE, Qian ZR, Ogino S. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr. 2016;115:1643–60. https://doi.org/10.1017/S0007114516000696.CrossRefPubMedPubMedCentral

383.

Wang H, Wang X, Xu L, Zhang J, Cao H. A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment. Aging (Albany NY). 2019;11:8587–603. https://doi.org/10.18632/aging.102349.CrossRefPubMed

384.

Ferrer-Mayorga G, Larriba MJ, Crespo P, Munoz A. Mechanisms of action of vitamin D in colon cancer. J Steroid Biochem Mol Biol. 2019;185:1–6. https://doi.org/10.1016/j.jsbmb.2018.07.002.CrossRefPubMed

385.

Carlberg C, Munoz A. An update on vitamin D signaling and cancer. Semin Cancer Biol. 2022;79:217–30. https://doi.org/10.1016/j.semcancer.2020.05.018.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Delineating the role of nuclear receptors in colorectal cancer, a focused review

Abstract

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

L-cysteine contributes to destructive activities of odontogenic cysts/tumor

Should we consider Systemic Inflammatory Response Index (SIRI) as a new diagnostic marker for rectal cancer?

Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6

Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer

Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials